No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BVS240517C7500
- 0.10
- 0.000.00%
15min DelayTrading May 7 13:43 ET
0.00High0.00Low
0.00Open0.10Pre Close0 Volume40 Open Interest7.50Strike Price0.00Turnover223.34%IV30.47%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type0.1616Delta0.1897Gamma58.25Leverage Ratio-0.0440Theta0.0001Rho9.41Eff Leverage0.0014Vega
Intraday
- 5D
- 1D
News
Bioventus: Poised for Growth Amidst Strategic Refinement and Debt Reduction
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.The company posted revenue of $1.
Apyx Medical Corporation Announces Board Leadership Transition
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Other Big Stocks Moving Lower
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.Shares of Exact Sciences Corporation (NASDAQ:EXAS) fell sharply in today's pre-market trading aft
Bioventus Is Maintained at Buy by Canaccord Genuity
Bioventus Is Maintained at Buy by Canaccord Genuity
Bioventus Price Target Raised to $8.00/Share From $7.00 by Canaccord Genuity
Bioventus Price Target Raised to $8.00/Share From $7.00 by Canaccord Genuity
Comments
The company’s quarterly sales reached $129.457 million, exceeding the analyst consensus estimate of $118.380 million by 9.36 percent.
Bioventus Inc. (Nasdaq: BVS), a company in the field of active healing solutions, has recently announced its financial outcomes for the quarter ending March 30, 2024, displaying remarkable performance and growth that has surpassed expectations on multiple fronts. The company's earnings pe...
Bioventus Inc. (Nasdaq: BVS), a company in the field of active healing solutions, has recently announced its financial outcomes for the quarter ending March 30, 2024, displaying remarkable performance and growth that has surpassed expectations on multiple fronts. The company's earnings pe...
$Bioventus(BVS.US$ Target 6
1
follow for nightly watchlist 👊
$Amgen(AMGN.US$ $Blue Apron(APRN.US$ $Broadcom(AVGO.US$ $Booking Holdings(BKNG.US$ $Bioventus(BVS.US$ $Caterpillar(CAT.US$ $Cohen(COHN.US$ $Freedom Holding(FRHC.US$ $F45 Training(FXLV.US$ $Globant(GLOB.US$ $AMTD Digital(HKD.US$ $Intuit(INTU.US$ $ServiceNow(NOW.US$ $Napco Security Technologies(NSSC.US$ $Sunrun(RUN.US$ $Schlumberger(SLB.US$
$Amgen(AMGN.US$ $Blue Apron(APRN.US$ $Broadcom(AVGO.US$ $Booking Holdings(BKNG.US$ $Bioventus(BVS.US$ $Caterpillar(CAT.US$ $Cohen(COHN.US$ $Freedom Holding(FRHC.US$ $F45 Training(FXLV.US$ $Globant(GLOB.US$ $AMTD Digital(HKD.US$ $Intuit(INTU.US$ $ServiceNow(NOW.US$ $Napco Security Technologies(NSSC.US$ $Sunrun(RUN.US$ $Schlumberger(SLB.US$
1
1
Read more